Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 3, 2005, Pages 1383-1389

  Catalano, Maria G ^a,b   Fortunati, Nicoletta ^a   Pugliese, Mariateresa ^a   Costantino, Lucia ^a   Poli, Roberta ^a   Bosco, Ornella ^b   Boccuzzi, Giuseppe ^a,b,c  

^a Sezione di Chirurgia Generale   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Dipto di Fisiopatologia Clinica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN A; VALPROIC ACID; CELL CYCLE PROTEIN; ENZYME INHIBITOR; HISTONE DEACETYLASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVATION; EPILEPSY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CANCER; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; PAPILLARY CARCINOMA; THYROID TUMOR; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, PAPILLARY; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; THYROID NEOPLASMS; VALPROIC ACID;

EID: 15944372866     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1355     Document Type: Article

References (41)

1. Goretzki PE, Simon D, Frilling A, Witte J, Reiners C, Grussendorf M, Hoster FA, Roher HD 1993 Surgical reintervention for differentiated thyroid carcinoma. Br J Surg 80:1009-1012
2. Schmutzler C, Koerhrle J 2000 Innovative strategies for the treatment of thyroid cancer. Eur J Endocrinol 143:15-24
3. Harada T, Kunihiko I, Shimako F 1977 Fatal thyroid carcinoma. Anaplastic transformation of adenocarcinoma. Cancer 39:2588-2596
4. Mazzaferri EL 1993 Undifferentiated thyroid carcinoma and unusual thyroid malignancies. In: Mazzaferri EL, Samaan NA, eds. Endocrine tumors. Boston: Blackwell Scientific Publications; 378-400
5. Vigushin DM, Coombes RC 2002 Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 12.1-13
6. Marks PA, Richon VM, Breslow R, Rifkind RA 2001 Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13:477-483
7. Rosato RR, Grant S 2003 Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2:30-37
8. De Ruijter AJ, van Gennip AH, Caron HN, Kemp S, Kuilenburg AB 2003 Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737-749
9. Gillenwater A, Zou CP, Zhong M, Lotan R 2000 Effect of sodium butyrate on growth, differentiation and apoptosis in head and neck squamous carcinoma cell lines. Head Neck 22:247-256
10. Romanski A, Basic B, Bug G, Pfeifer H, Gul H, Remiszewski S, Hoelzer D, Atadja P, Ruthardt M, Ottmann OG 2004 Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 89:419-426
11. Sato N, Otha T, Kitawaga M, Ninomiya J, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K 2004 FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 24:679-685
12. Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, Hautmann RE, Gschwend JE 2004 Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 90:535-541
13. Richon VM, Sandhoff TW, Rifkind RA, Marks PA 2000 Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97:10014-10019
14. Phiel CJ, Zhang F, Huamg EY, Guenther MG, Lazar MA, Klein PS 2001 Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen. J Biol Chem 276:36734-36741
15. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK 2001 Histone deacetylases and cancer: causes and therapies. Nature 1:194-202
16. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T 2001 Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978
17. Chapman A, Keane PE, Meldrum BS, Simiand J, Verniers JC 1982 Mechanism of anticonvulsant action of valproate. Prog Neurobiol 19:315-359
18. Claus R, Lubbert M 2003 Epigenetic targets in hematopoietic malignancies. Oncogene 22:6489-6496
19. Cinatl Jr J, Kotchetkov R, Blaheta R, Driever PH, Vogel JU, Cinatl J 2002 Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE (2)-C cells by valproic acid: enhancement by combination with interferon α. Int J Oncol 20:97-106
20. - symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 82:1006-1009
21. Slesinger PA, Singer HS 1987 Effect of anticonsivants on cell growth and enzymatic and receptor binding activity in neuroblastoma X glioma hybrid cell culture. Epilepsia 28:214-221
22. Knupfer MM, Hernaiz-Driever P, Poppenborg H, Woiff JE, Cinafl J 1988 Valproic acid inhibits proliferation and changes expression of CD44 and CD 56 of malignant glioma cells in vitro. Anticancer Res 18:3585-3589
23. Abdul M, Hoosein N 2001 Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells. Anticancer Res 21:2045-2048
24. Olsen CM, Meussen-Elhom ETM, Roste LS, Tauboll E 2004 Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF-7. Mol Cell Endocrinol 213:173-179
25. Kawagoe R, Kawagoe H, Sano K 2002 Valproic acid induces apoptosis in human leukaemia cells by stimulating both caspase-dependent and -independent apoptotic signalling pathways. Leuk Res 26:495-502
26. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Koeffler HP 2004 Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10:1141-1149
27. Mosmann T 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63
28. Chomczynski P, Sacchi N 1987 Single step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
29. Known SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee HW, Han JW 2002 Apicidin, a histone deacetylase inhibitor, induces apoptosis and FAS/FAS ligand expression in human acute promielocytic leukemia cells. J Biol Chem 277:2073-2080
30. Aron JL, Parthun MR, Marucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM, Reed JC, Grever MR, Byrd JC 2003 Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cell concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102:652-658
31. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, Grant S 1999 Induction of apoptosis in U937 human leukemia cells by superoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by BCL-2/BCL-XL, c-JUN and p21CIP, but independent of p53. Oncogene 18:7016-7025
32. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Taiton KM, Kofler R, Smyth MJ, Johnstone RW 2001 The histone deacetylase inhibitor and chemiothepeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of BID and production of reactive oxygen species. Proc Natl Acad Sci USA 98:10833-30838
33. CIP1/WAF1. Cancer Res 63:3637-3645
34. Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD, Flax AL, Wickham J, Reed JC, Byrd JC, Grever MR 2004 The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18:1207-1214
35. Greenberg VL, Williams JM, Cogswell JP, Mendenhall M, Zimmer SG 2001 Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 11:315-322
36. Sambucetti LC, Fisher DD, Zabludoff S, Known PO, Chamberlin H, Trogani N, Xu H, Cohen D 1999 Histone deacetylase inhibition selectively alters the activity and expression of the cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274:34940-34947
37. Saito A, Yamashita T, Makiro Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O 1999 A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vitro antitumor activity against human tumors. Proc Natl Acad Sci USA 96:4592-4597
38. Kim YB, Ki SW, Yoshida M, Horinouchi S 2000 Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J Antibiot (Tokyo) 53:1191-1200
39. 1 arrest results from p21-independent disruption of retinobalstoma protein-mediated signals. Cell Growth Differ 9:465-474
40. Johnstone RW, Licht JD 2003 Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4:13-18
41. Johnstone RW 2002 Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299